Insider Trading activities of Endocyte Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Endocyte Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Endocyte Inc since year 2005. Table 2 shows the detailed insider transactions of Endocyte Inc since 2005. The reporting company's ticker symbol is ECYT. The reporting company's CIK number is 1235007.
The total value of stock buying since 2005 is $12,275,511.
The total value of stock sales since 2005 is $7,825,299.
The total value of stock option exercises since 2005 is $1,505,437.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Endocyte Inc (ECYT).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-12 0 $0 23,231 $117,107 26,178 $80,104
2017-11 5,600 $27,104 0 $0 0 $0
2017-05 0 $0 0 $0 44,285 $92,998
2016-12 0 $0 23,244 $59,272 26,178 $54,973
2016-11 0 $0 0 $0 15,706 $32,982
2016-07 0 $0 0 $0 10,471 $19,999
2016-01 30,000 $83,900 0 $0 0 $0
2015-12 0 $0 0 $0 13,089 $24,999
2015-03 0 $0 29,883 $172,992 40,000 $142,000
2015-02 0 $0 0 $0 65,989 $298,812
2014-11 0 $0 0 $0 19,060 $36,404
2014-10 0 $0 0 $0 14,927 $38,317
2014-08 0 $0 21,479 $150,353 21,479 $70,988
2014-04 0 $0 1,000 $21,160 22,560 $58,204
2014-03 0 $0 8,000 $264,880 80,000 $152,800
2014-02 0 $0 6,000 $90,000 1,000 $1,910
2014-01 0 $0 0 $0 1,000 $1,910
2013-12 0 $0 3,000 $36,000 4,000 $7,640
2013-11 0 $0 3,000 $36,000 4,000 $7,640
2013-10 0 $0 3,000 $39,900 4,000 $7,640
2013-09 0 $0 15,000 $232,740 14,000 $94,940
2013-08 0 $0 16,000 $261,550 16,000 $37,300
2013-07 0 $0 3,000 $51,030 3,000 $5,730
2013-05 0 $0 151,083 $2,184,736 25,000 $81,500
2013-04 0 $0 1,500 $19,120 0 $0
2013-03 0 $0 2,500 $29,000 12,722 $24,299
2013-02 0 $0 3,102 $30,404 2,102 $5,875
2013-01 0 $0 3,209 $31,118 2,209 $5,986
2012-12 0 $0 10,209 $91,791 2,209 $5,610
2012-11 0 $0 9,209 $84,262 2,209 $5,610
2012-10 0 $0 2,209 $21,449 2,209 $5,610
2012-09 0 $0 36,209 $362,504 2,209 $5,610
2012-08 0 $0 10,000 $96,530 0 $0
2012-06 0 $0 325,100 $2,146,634 0 $0
2012-05 0 $0 174,900 $1,194,767 0 $0
2011-12 666,000 $2,139,799 0 $0 42,940 $72,015
2011-08 0 $0 0 $0 14 $2
2011-04 0 $0 0 $0 13,983 $18,667
2011-03 0 $0 0 $0 20,073 $6,363
2011-02 1,670,686 $10,024,708 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Endocyte Inc insiders (ECYT)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-12-01 Leamon Christopher P (Vice President of Research) Sale 23,231 5.04 117,107
2017-12-01 Leamon Christopher P (Vice President of Research) Option Ex 26,178 3.06 80,104
2017-11-13 Low Philip S (Chief Science Officer) Buy 5,600 4.84 27,104
2017-05-31 Sherman Michael A. (President, CEO and CFO) Option Ex 44,285 2.10 92,998
2016-12-30 Leamon Christopher P (Vice President of Research) Sale 23,244 2.55 59,272
2016-12-30 Leamon Christopher P (Vice President of Research) Option Ex 26,178 2.10 54,973
2016-11-15 Low Philip S (Chief Science Officer) Option Ex 15,706 2.10 32,982
2016-07-27 Brauer Keith E Option Ex 10,471 1.91 19,999
2016-01-19 Middleton Fred A Buy 10,000 2.79 27,900
2016-01-15 Middleton Fred A Buy 20,000 2.80 56,000
2015-12-24 Low Philip S (Chief Science Officer) Option Ex 13,089 1.91 24,999
2015-03-03 Nguyen Binh (VP of Medical Affairs) Sale 29,883 5.79 172,992
2015-03-03 Nguyen Binh (VP of Medical Affairs) Option Ex 40,000 3.55 142,000
2015-02-10 Low Philip S (Chief Science Officer) Option Ex 544 1.91 1,039
2015-02-10 Leamon Christopher P (Vice President of Research) Option Ex 13,089 1.91 24,999
2015-02-06 Ellis P Ron (President and CEO) Option Ex 52,356 5.21 272,774
2014-11-05 Ellis P Ron (President and CEO) Option Ex 19,060 1.91 36,404
2014-10-31 Sherman Michael A. (COO and CFO) Option Ex 14,927 2.57 38,317
2014-08-11 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 21,479 7.00 150,353
2014-08-11 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 21,479 3.31 70,988
2014-04-10 Ritter Allen R (VP of Manufacturing/CMC) Option Ex 22,560 2.58 58,204
2014-04-09 Ritter Allen R (VP of Manufacturing/CMC) Sale 1,000 21.16 21,160
2014-03-21 Ritter Allen R (VP of Manufacturing/CMC) Sale 8,000 33.11 264,880
2014-03-10 Ellis P Ron (President and CEO) Option Ex 80,000 1.91 152,800
2014-02-14 Low Philip S (Chief Science Officer) Sale 6,000 15.00 90,000
2014-02-11 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2014-01-14 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2013-12-17 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2013-12-04 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-12-02 Ellis P Ron (President and CEO) Sale 3,000 12.00 36,000
2013-11-12 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2013-11-07 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-11-06 Ellis P Ron (President and CEO) Sale 3,000 12.00 36,000
2013-10-15 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2013-10-02 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-10-01 Ellis P Ron (President and CEO) Sale 3,000 13.30 39,900
2013-09-24 Low Philip S (Chief Science Officer) Option Ex 1,000 1.91 1,910
2013-09-16 Ritter Allen R (VP of Manufacturing/CMC) Sale 2,000 17.06 34,120
2013-09-12 Meek David D. (Chief Commercial Officer) Sale 10,000 15.50 155,000
2013-09-12 Meek David D. (Chief Commercial Officer) Option Ex 10,000 8.73 87,300
2013-09-04 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-09-03 Ellis P Ron (President and CEO) Sale 3,000 14.54 43,620
2013-08-30 Ritter Allen R (VP of Manufacturing/CMC) Sale 6,000 14.36 86,160
2013-08-30 Ritter Allen R (VP of Manufacturing/CMC) Option Ex 6,000 2.10 12,600
2013-08-06 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 7,000 17.29 121,030
2013-08-06 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 7,000 2.71 18,970
2013-08-02 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-08-01 Ellis P Ron (President and CEO) Sale 3,000 18.12 54,360
2013-07-16 Ellis P Ron (President and CEO) Option Ex 3,000 1.91 5,730
2013-07-15 Ellis P Ron (President and CEO) Sale 3,000 17.01 51,030
2013-05-28 Hanham Ann Sale 1,700 14.25 24,225
2013-05-24 Hanham Ann Sale 8,200 14.07 115,374
2013-05-23 Ritter Allen R (VP of Manufacturing/CMC) Option Ex 5,000 2.10 10,500
2013-05-22 Nguyen Binh (VP of Clinical Affairs) Option Ex 2,700 3.55 9,585
2013-05-22 Hanham Ann Sale 16,400 14.39 235,996
2013-05-21 Ritter Allen R (VP of Manufacturing/CMC) Sale 483 14.17 6,844
2013-05-21 Hanham Ann Sale 11,000 14.31 157,410
2013-05-20 Hanham Ann Sale 12,600 14.42 181,692
2013-05-17 Nguyen Binh (VP of Clinical Affairs) Sale 17,300 14.42 249,466
2013-05-17 Nguyen Binh (VP of Clinical Affairs) Option Ex 17,300 3.55 61,415
2013-05-17 Hanham Ann Sale 14,600 14.37 209,802
2013-05-16 Hanham Ann Sale 22,600 14.44 326,344
2013-05-15 Hanham Ann Sale 20,000 14.43 288,600
2013-05-14 Leamon Christopher P (Vice President of Research) Sale 5,000 14.70 73,500
2013-05-14 Hanham Ann Sale 20,200 14.94 301,788
2013-05-07 Ritter Allen R (VP of Manufacturing/CMC) Sale 500 13.51 6,755
2013-05-01 Ellis P Ron (President and CEO) Sale 500 13.88 6,940
2013-04-16 Ritter Allen R (VP of Manufacturing/CMC) Sale 500 13.22 6,610
2013-04-02 Ritter Allen R (VP of Manufacturing/CMC) Sale 500 12.48 6,240
2013-04-01 Ellis P Ron (President and CEO) Sale 500 12.54 6,270
2013-03-27 Ellis P Ron (President and CEO) Sale 1,500 12.00 18,000
2013-03-25 Ritter Allen R (VP of Manufacturing/CMC) Sale 1,000 11.00 11,000
2013-03-13 Ritter Allen R (VP of Manufacturing/CMC) Option Ex 12,722 1.91 24,299
2013-02-25 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,102 9.70 20,389
2013-02-25 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,102 2.79 5,875
2013-02-19 Ritter Allen R (VP of Manufacturing/CMC) Sale 500 10.03 5,015
2013-02-15 Ritter Allen R (VP of Manufacturing/CMC) Sale 500 10.00 5,000
2013-01-31 Ritter Allen R (VP of Manufacturing/CMC) Sale 1,000 10.00 10,000
2013-01-25 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,209 9.56 21,118
2013-01-25 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,209 2.71 5,986
2012-12-31 Ellis P Ron (President and CEO) Sale 6,000 8.75 52,500
2012-12-26 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,209 9.05 19,991
2012-12-26 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,209 2.54 5,610
2012-12-18 Ritter Allen R (VP of Manufacturing/CMC) Sale 2,000 9.65 19,300
2012-11-26 Ritter Allen R (VP of Manufacturing/CMC) Sale 2,000 9.00 18,000
2012-11-26 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,209 8.72 19,262
2012-11-26 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,209 2.54 5,610
2012-11-01 Ritter Allen R (VP of Manufacturing/CMC) Sale 5,000 9.40 47,000
2012-10-25 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,209 9.71 21,449
2012-10-25 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,209 2.54 5,610
2012-09-28 Low Philip S (Chief Science Officer) Sale 34,000 9.99 339,796
2012-09-25 Lovejoy Chandra D (VP of Regulatory Affairs) Sale 2,209 10.28 22,708
2012-09-25 Lovejoy Chandra D (VP of Regulatory Affairs) Option Ex 2,209 2.54 5,610
2012-08-16 Leamon Christopher P (Vice President of Research) Sale 10,000 9.65 96,530
2012-06-06 Hanham Ann (Director) Sale 314,900 6.60 2,079,284
2012-06-05 Hanham Ann (Director) Sale 10,200 6.60 67,350
2012-05-16 Hanham Ann (Director) Sale 27,900 6.65 185,562
2012-05-15 Hanham Ann (Director) Sale 40,000 6.68 267,160
2012-05-14 Hanham Ann (Director) Sale 107,000 6.93 742,045
2011-12-21 Sanderling V Strategic Exit Fund Lp (10% Owner) Buy 217,800 3.16 688,248
2011-12-21 Leamon Christopher P (Vice President of Research) Buy 5,000 3.14 15,700
2011-12-21 Sanderling Ventures Management Vi (10% Owner) Buy 2,200 3.16 6,952
2011-12-20 Sanderling V Strategic Exit Fund Lp (10% Owner) Buy 217,800 3.20 696,960
2011-12-20 Sanderling Ventures Management Vi (10% Owner) Buy 2,200 3.20 7,040
2011-12-20 Middleton Fred A (Director) Buy 916 3.18 2,912
2011-12-19 Middleton Fred A (Director) Buy 24,084 3.13 75,382
2011-12-16 Low Philip S (Chief Science Officer) Buy 1,000 3.21 3,205
2011-12-16 Sherman Michael A. (Chief Financial Officer) Option Ex 20,942 2.00 41,988
2011-12-16 Ellis P Ron (President and CEO) Option Ex 21,998 1.36 30,027
2011-12-16 Middleton Fred A (Director) Buy 50,000 3.16 158,000
2011-12-16 Bailey Douglas G (Director) Buy 125,000 3.36 420,000
2011-12-16 Aplin John C (Director) Buy 20,000 3.27 65,400
2011-08-05 Ellis P Ron (President and CEO) Option Ex 14 .19 2
2011-04-18 Ritter Allen R (VP of Manufacturing/CMC) Option Ex 13,983 1.33 18,667
2011-03-24 Leamon Christopher P (Vice President of Research) Option Ex 20,073 .32 6,363
2011-02-07 Middleton Fred A (Director) Buy 833,333 6.00 4,999,998
2011-02-04 Low Philip S (Chief Science Officer) Buy 1,520 6.39 9,712
2011-02-04 Ellis P Ron (President and CEO) Buy 2,500 6.00 15,000
2011-02-04 Sanderling Ventures Management Vi (10% Owner) Buy 47,916 6.00 287,496
2011-02-04 Sanderling Vi Limited Partnership (10% Owner) Buy 785,417 6.00 4,712,502

Insider trading activities including stock purchases, stock sales, and option exercises of ECYT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Endocyte Inc (symbol ECYT, CIK number 1235007) see the Securities and Exchange Commission (SEC) website.